Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
2.41
-0.19 (-7.31%)
After Hours: 2.41 0.00 (0.00%)
Dec 9, 4:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.32 - 2.66
52 week 2.32 - 49.80
Open 2.60
Vol / Avg. 515,136.00/390,620.00
Mkt cap 26.05M
P/E     -
Div/yield     -
EPS -2.32
Shares 10.85M
Beta 2.96
Inst. own 22%
Mar 8, 2017
Q4 2016 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 30, 2017
Galena Biopharma Inc at Noble Financial Emerging Growth Investor Conference Add to calendar
Jan 9, 2017
Galena Biopharma Inc at EBD Group Biotech Showcase Add to calendar
Dec 1, 2016
Galena Biopharma Inc at PR Newswire and BetterInvesting (NAIC) Investor Conference
Nov 9, 2016
Q3 2016 Galena Biopharma Inc Earnings Call - Webcast
Nov 9, 2016
Q3 2016 Galena Biopharma Inc Earnings Release
Sep 28, 2016
Galena Biopharma Inc at Sachs Biotech in Europe Forum
Sep 22, 2016
Galena Biopharma Inc at Aegis Capital Growth Conference - Webcast
Sep 13, 2016
Galena Biopharma Inc at Rodman & Renshaw Global Investment Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -23.76% -47.91%
Return on average equity -78.71% -154.06%
Employees 22 -
CDP Score - -

Address

4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Stephen F. Ghiglieri Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Thomas J. Knapp Interim General Counsel, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 74
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters